NASDAQ:BTAI - Nasdaq - US09075P2048 - Common Stock - Currency: USD
1.39
-0.03 (-2.11%)
The current stock price of BTAI is 1.39 USD. In the past month the price decreased by -17.75%. In the past year, price decreased by -95.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.7 | 321.60B | ||
AMGN | AMGEN INC | 13.07 | 145.89B | ||
GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
ONC | BEIGENE LTD-ADR | 5.88 | 25.49B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.54B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
BIIB | BIOGEN INC | 8.02 | 18.58B |
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 37
Phone: 12036438060
The current stock price of BTAI is 1.39 USD. The price decreased by -2.11% in the last trading session.
The exchange symbol of BIOXCEL THERAPEUTICS INC is BTAI and it is listed on the Nasdaq exchange.
BTAI stock is listed on the Nasdaq exchange.
12 analysts have analysed BTAI and the average price target is 28.05 USD. This implies a price increase of 1917.99% is expected in the next year compared to the current price of 1.39. Check the BIOXCEL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOXCEL THERAPEUTICS INC (BTAI) has a market capitalization of 7.60M USD. This makes BTAI a Nano Cap stock.
BIOXCEL THERAPEUTICS INC (BTAI) currently has 37 employees.
BIOXCEL THERAPEUTICS INC (BTAI) has a resistance level at 1.46. Check the full technical report for a detailed analysis of BTAI support and resistance levels.
The Revenue of BIOXCEL THERAPEUTICS INC (BTAI) is expected to grow by 1.84% in the next year. Check the estimates tab for more information on the BTAI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BTAI does not pay a dividend.
BIOXCEL THERAPEUTICS INC (BTAI) will report earnings on 2025-08-04.
BIOXCEL THERAPEUTICS INC (BTAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.55).
The outstanding short interest for BIOXCEL THERAPEUTICS INC (BTAI) is 1.78% of its float. Check the ownership tab for more information on the BTAI short interest.
ChartMill assigns a fundamental rating of 1 / 10 to BTAI. BTAI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -13.55. The EPS increased by 83.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -103.88% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 73% to BTAI. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 31.95% and a revenue growth 1.84% for BTAI